 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...197198199200201202203204205206207208209» |
- || AiTan (rivoceranib) / HLB Bio Group
New P3 trial: A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (clinicaltrials.gov) - Jul 6, 2016
P3, N=246, Recruiting, Sponsor: Sun Yat-sen University
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: the Food Effect Pharmacokinetic, Material Balance and Metabolite Identification of SP2086 in Healthy Volunteers (clinicaltrials.gov) - Jul 5, 2016
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients (clinicaltrials.gov) - Jul 5, 2016
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The DDI Study of SP2086 and Valsartan (clinicaltrials.gov) - Jun 29, 2016
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The DDI Study of SP2086 and Simvastatin (clinicaltrials.gov) - Jun 29, 2016
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Drug-drug Interaction of SP2086 and Valsartan (clinicaltrials.gov) - Jun 28, 2016
P1, N=16, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Drug-drug Interaction of SP2086 and Simvastatin (clinicaltrials.gov) - Jun 28, 2016
P1, N=16, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Metabolite Identification and Material Balance Study of SP2086 (clinicaltrials.gov) - Jun 28, 2016
P1, N=8, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: SP2086 Pharmacokinetic Study in Renal Insufficiency Patients (clinicaltrials.gov) - Jun 28, 2016
P1, N=30, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Drug -Drug Interaction of SP2086 and Glyburide (clinicaltrials.gov) - Jun 28, 2016
P1, N=16, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
New P1 trial: Single Dose Study of SHR4640 in Healthy Subjects (clinicaltrials.gov) - Jun 28, 2016
P1, N=50, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Ruizetang (retagliptin) / Jiangsu Hengrui Pharma
New P1 trial: The Drug-drug Interaction of SP2086 and Metformin (clinicaltrials.gov) - Jun 27, 2016
P1, N=24, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Opdivo (nivolumab) / Ono Pharma, BMS, plinabulin (BPI 2358) / BeyondSpring
New P1 trial: Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 24, 2016
P1, N=38, Not yet recruiting, Sponsor: Lyudmila Bazhenova, M.D.
- ||| Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
Enrollment closed: CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED) (clinicaltrials.gov) - Jun 11, 2016
P2, N=207, Active, not recruiting, Sponsor: Novaliq GmbH
Recruiting --> Active, not recruiting
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Trial primary completion date: Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer (clinicaltrials.gov) - Jun 10, 2016
P1, N=40, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2015 --> Jul 2016
- ||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Enrollment closed: A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab (clinicaltrials.gov) - Jun 9, 2016
P1/2, N=128, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial primary completion date: Sep 2015 --> Jul 2016 Not yet recruiting --> Active, not recruiting
- AiTan (rivoceranib) / HLB Bio Group
New P2/3 trial: Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer (clinicaltrials.gov) - May 23, 2016
P2/3, N=20, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects (clinicaltrials.gov) - May 18, 2016
P1, N=36, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients. (clinicaltrials.gov) - May 18, 2016
P2, N=20, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- AiTan (rivoceranib) / HLB Bio Group
New P4 trial, Metastases: A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy (clinicaltrials.gov) - May 18, 2016
P4, N=40, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Metastases: A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck (clinicaltrials.gov) - May 18, 2016
P2, N=60, Not yet recruiting, Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma (clinicaltrials.gov) - May 13, 2016
P1, N=36, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- AiTan (rivoceranib) / HLB Bio Group
New P1/2 trial, Metastases: A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure (clinicaltrials.gov) - May 13, 2016
P1/2, N=30, Not yet recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
- AiTan (rivoceranib) / HLB Bio Group, Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
New P2 trial: Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer (clinicaltrials.gov) - May 11, 2016
P2, N=40, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- |||||||||| famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P3 trial: SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer (clinicaltrials.gov) - May 9, 2016
P3, N=574, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| AiTan (rivoceranib) / HLB Bio Group
New trial, Metastases: Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - May 6, 2016
P=N/A, N=60, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P1 trial: A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - May 3, 2016
P1, N=21, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment change: Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors (clinicaltrials.gov) - May 2, 2016
P1, N=70, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting N=40 --> 70
- AiTan (rivoceranib) / HLB Bio Group
Phase classification, Trial initiation date, Trial primary completion date, Metastases: Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301) (clinicaltrials.gov) - Apr 28, 2016
P2, N=80, Not yet recruiting, Sponsor: Chinese PLA General Hospital
N=40 --> 70 Phase classification: P2/3 --> P2 | Initiation date: Nov 2015 --> Apr 2016 | Trial primary completion date: Dec 2016 --> Apr 2017
- AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects (clinicaltrials.gov) - Apr 27, 2016
P1, N=45, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Phase classification: P2/3 --> P2 | Initiation date: Nov 2015 --> Apr 2016 | Trial primary completion date: Dec 2016 --> Apr 2017 Not yet recruiting --> Recruiting
- | noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
New P1 trial: Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic Patients (clinicaltrials.gov) - Apr 25, 2016
P1, N=12, Recruiting, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- ||| noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Volunteers (clinicaltrials.gov) - Apr 21, 2016
P1, N=62, Completed, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- | noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese Volunteers (clinicaltrials.gov) - Apr 21, 2016
P1, N=40, Completed, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- | AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P1 trial: A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer (clinicaltrials.gov) - Apr 21, 2016
P1, N=27, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||| AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
Enrollment open: A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients (clinicaltrials.gov) - Apr 20, 2016
P1/2, N=140, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Metastases: Ahead-G201: A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Apr 19, 2016
P4, N=2000, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Trial initiation date: Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients (clinicaltrials.gov) - Apr 19, 2016
P1, N=48, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Recruiting Initiation date: Feb 2016 --> May 2016
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1 trial: A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects (clinicaltrials.gov) - Apr 19, 2016
P1, N=36, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1 trial: A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma (clinicaltrials.gov) - Apr 14, 2016
P1, N=36, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Enrollment open: A Study of SHR6390 in Advanced Solid Tumor Patients (clinicaltrials.gov) - Apr 12, 2016
P1, N=40, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Initiation date: Feb 2016 --> May 2016 Not yet recruiting --> Recruiting
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Enrollment open, Metastases: A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients (clinicaltrials.gov) - Apr 12, 2016
P1, N=30, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial: The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer (clinicaltrials.gov) - Apr 11, 2016
P2, N=25, Recruiting, Sponsor: Third Military Medical University
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Study of Apatinib in Patients With Differentiated Thyroid Cancer (clinicaltrials.gov) - Apr 7, 2016
P2, N=10, Recruiting, Sponsor: Peking Union Medical College Hospital
- AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apslpanc: Apatinib as Second-line Treatment of Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 4, 2016
P2, N=30, Not yet recruiting, Sponsor: First Affiliated Hospital Xi'an Jiaotong University
- | AiTan (rivoceranib) / HLB Bio Group
New P1/2 trial, Metastases: A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients (clinicaltrials.gov) - Apr 4, 2016
P1/2, N=30, Recruiting, Sponsor: Beijing Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Metastases: Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301) (clinicaltrials.gov) - Mar 30, 2016
P2/3, N=80, Recruiting, Sponsor: Chinese PLA General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P1 trial: A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects (clinicaltrials.gov) - Mar 29, 2016
P1, N=45, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- AiTan (rivoceranib) / HLB Bio Group
Enrollment open: Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 23, 2016
P1, N=9, Recruiting, Sponsor: Peking University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- AiTan (rivoceranib) / HLB Bio Group
New P2/3 trial: Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy (clinicaltrials.gov) - Mar 18, 2016
P2/3, N=37, Recruiting, Sponsor: GUO WEI
- AiTan (rivoceranib) / HLB Bio Group
New P1 trial, Metastases: A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment (clinicaltrials.gov) - Mar 18, 2016
P1, N=6, Not yet recruiting, Sponsor: Bukwang Pharmaceutical